CERENOME, Regulatory Monday, November 16, 2026 +0.50 Positive

Cerenome Reports Safe Repeat REYOBIQ Dosing in LM Study

Cerenome reported zero dose-limiting toxicities and consistent delivery across repeat treatments for the first 10 leptomeningeal metastases patients. The early data are encouraging as the company advances dose escalation toward a future randomized study.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed